Congenital muscular dystrophies: New aspects of an expanding group of disorders

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1772, Issue 2, 2007, Pages 159-172

  Lisi, Matthew T ^a   Cohn, Ronald D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dystroglycan; Integrins; Laminin 2; Muscular dystrophy; Selenoprotein N

Indexed keywords

ALPHA DYSTROGLYCAN; ALPHA7 INTEGRIN; LAMININ; LAMININ ALPHA2; LAMININ ALPHA4; SELENOCYSTEINE; UNCLASSIFIED DRUG;

BRAIN DISEASE; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; EYE DISEASE; GENE MUTATION; HUMAN; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; REVIEW;

ANIMALS; HUMANS; MUSCULAR DYSTROPHIES;

EID: 33846265912     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2006.09.006     Document Type: Review

References (149)

1. Batten F. Three cases of myopathy, infantile type. Brain 26 (1903) 147-148
2. Voit T., and Tome F. The congenital muscular dystrophy. Myolog, Engel., A (2004)
3. Jimenez-Mallebrera C., Brown S.C., Sewry C.A., and Muntoni F. Congenital muscular dystrophy: molecular and cellular aspects. Cell. Mol. Life Sci. 62 (2005) 809-823
4. Muntoni F., and Voit T. The congenital muscular dystrophies in 2004: a century of exciting progress. Neuromuscul. Disord. 10 (2004) 635-649
5. Helbling-Leclerc A., Zhang X., Topaloglu H., Cruaud C., Tesson F., Weissenbach J., Tome F.M., Schwartz K., Fardeau M., Tryggvason K., et al. Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nat. Genet. 11 (1995) 216-218
6. Tome F.M., Evangelista T., Leclerc A., Sunada Y., Manole E., Estournet B., Barois A., Campbell K.P., and Fardeau M. Congenital muscular dystrophy with merosin deficiency. C. R. Acad. Sci., III 317 (1994) 351-357
7. Colognato H., and Yurchenco P.D. Form and function: the laminin family of heterotrimers. Dev. Dyn. 218 (2000) 213-234
8. Yurchenco P.D., Cheng Y.S., Campbell K., and Li S. Loss of basement membrane, receptor and cytoskeletal lattices in a laminin-deficient muscular dystrophy. J. Cell. Sci. 117 (2004) 735-742
9. Hillaire D., Leclerc A., Faure S., Topaloglu H., Chiannilkulchai N., Guicheney P., Grinas L., Legos P., Philpot J., Evangelista T., et al. Localization of merosin-negative congenital muscular dystrophy to chromosome 6q2 by homozygosity mapping. Hum. Mol. Genet. 9 (1994) 1657-1661
10. Ehrig K., Leivo I., Argraves W.S., Ruoslahti E., and Engvall E. Merosin, a tissue-specific basement membrane protein, is a laminin-like protein. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 3264-3268
11. Vuolteenaho R., Nissinen M., Sainio K., Byers M., Eddy R., Hirvonen H., Shows T.B., Sariola H., Engvall E., and Tryggvason K. Human laminin M chain (merosin): complete primary structure, chromosomal assignment, and expression of the M and A chain in human fetal tissues. J. Cell Biol. 124 (1994) 381-394
12. Zhang X., Vuolteenaho R., and Tryggvason K. Structure of the human laminin alpha2-chain gene (LAMA2), which is affected in congenital muscular dystrophy. J. Biol. Chem. 271 (1996) 27664-27669
13. Patton B.L., Miner J.H., Chiu A.Y., and Sanes J.R. Distribution and function of laminins in the neuromuscular system of developing, adult, and mutant mice. J. Cell Biol. 139 (1997) 1507-1521
14. Sewry C.A. The role of immunocytochemistry in congenital myopathies. Neuromuscul. Disord. 6 (1998) 394-400
15. Talts J.F., Andac Z., Gohring W., Brancaccio A., and Timpl R. Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins. EMBO J. 18 (1999) 863-870
16. Henry M.D., Satz J.S., Brakebusch C., Costell M., Gustafsson E., Fassler R., and Campbell K.P. Distinct roles for dystroglycan, beta1 integrin and perlecan in cell surface laminin organization. J. Cell. Sci. 114 (2001) 1137-1144
17. Hayashi Y.K., Koga R., Tsukahara T., Ishii H., Matsuishi T., Yamashita Y., Nonaka I., and Arahata K. Deficiency of laminin alpha 2-chain mRNA in muscle in a patient with merosin-negative congenital muscular dystrophy. Muscle Nerve (1995) 1027-1030
18. Pegoraro E., Fanin M., Trevisan C.P., Angelini C., and Hoffman E.P. A novel laminin alpha2 isoform in severe laminin alpha2 deficient congenital muscular dystrophy. Neurology 55 (2000) 1128-1134
19. Leite C.C., Lucato L.T., Martin M.G., Ferreira L.G., Resende M.B., Carvalho M.S., Marie S.K., Jinkins J.R., and Reed U.C. Merosin-deficient congenital muscular dystrophy (CMD): a study of 25 Brazilian patients using MRI. Pediatr. Radiol. 35 (2005) 572-579
20. Philpot J., Cowan F., Pennock J., Sewry C., Dubowitz V., Bydder G., and Muntoni F. Merosin-deficient congenital muscular dystrophy: the spectrum of brain involvement on magnetic resonance imaging. Neuromuscul. Disord. 9 (1999) 81-85
21. Taratuto A.L., Lubieniecki F., Diaz D., Schultz M., Ruggieri V., Saccoliti M., and Dubrovsky A. Merosin-deficient congenital muscular dystrophy associated with abnormal cerebral cortical gyration: an autopsy study. Neuromuscul. Disord. 9 (1999) 86-94
22. Gilhuis H.J., ten Donkelaar H.J., Tanke R.B., Vingerhoets D.M., Zwarts M.J., Verrips A., and Gabreels F.J. Nonmuscular involvement in merosin-negative congenital muscular dystrophy. Pediatr. Neurol. 26 (2002) 30-36
23. Spyrou N., Philpot J., Foale R., Camici P.G., and Muntoni F. Evidence of left ventricular dysfunction in children with merosin-deficient congenital muscular dystrophy. Am. Heart J. 136 (1998) 474-476
24. Mercuri E., Dubowitz L., Berardinelli A., Pennock J., Jongmans M., Henderson S., Muntoni F., Sewry C., Philpot J., and Dubowitz. V. Minor neurological and perceptuo-motor deficits in children with congenital muscular dystrophy: correlation with brain MRI changes. Neuropediatrics (1995) 156-162
25. Philpot J., and Muntoni F. Limitation of eye movement in merosin-deficient congenital muscular dystrophy. Lancet 353 (1999) 297-298
26. Cohn R.D., Herrmann R., Sorokin L., Wewer U.M., and Voit T. Laminin alpha2 chain-deficient congenital muscular dystrophy: variable epitope expression in severe and mild cases. Neurology 51 (1998) 94-100
27. Sewry C.A., Naom I., D'Alessandro M., Sorokin L., Bruno S., Wilson L.A., Dubowitz V., and Muntoni F. Variable clinical phenotype in merosin-deficient congenital muscular dystrophy associated with differential immunolabelling of two fragments of the laminin alpha 2 chain. Neuromuscul. Disord. 7 (1998) 169-175
28. Cohn R.D., Herrmann R., Wewer U.M., and Voit T. Changes of laminin beta 2 chain expression in congenital muscular dystrophy. Neuromuscul. Disord. 6-7 (1997) 373
29. Cohn R.D., Mayer U., Saher G., Herrmann R., van der Flier A., Sonnenberg A., Sorokin L., and Voit T. Secondary reduction of alpha7B integrin in laminin alpha2 deficient congenital muscular dystrophy supports an additional transmembrane link in skeletal muscle. J. Neurol. Sci. 163 (1999) 140-152
30. Patton B.L., Connolly A.M., Martin P.T., Cunningham J.M., Mehta S., Pestronk A., Miner J.H., and Sanes J.R. Distribution of ten laminin chains in dystrophic and regenerating muscles. Neuromuscul. Disord. 6-7 (1999) 423-433
31. Vachon P.H., Xu H., Liu L., Loechel F., Hayashi Y., Arahata K., Reed J.C., Wewer U.M., and Engvall E. Integrins (alpha7beta1) in muscle function and survival. Disrupted expression in merosin-deficient congenital muscular dystrophy. J. Clin. Invest. 100 (1997) 1870-1881
32. Sewry C.A., D'Alessandro M., Wilson L.A., Sorokin L.M., Naom I., Bruno S., Ferlini A., Dubowitz V., and Muntoni F. Expression of laminin chains in skin in merosin-deficient congenital muscular dystrophy. Neuropediatrics 28 (1998) 217-222
33. Naom I., D'Alessandro M., Sewry C., Ferlini A., Topaloglu H., Helbling-Leclerc A., Guicheney P., Schwartz K., Akcoren Z., Dubowitz V., and Muntoni F. The role of immunocytochemistry and linkage analysis in the prenatal diagnosis of merosin-deficient congenital muscular dystrophy. Hum. Genet. 99 (1997) 535-540
34. Naom I., Sewry C., D'Alessandro M., Topaloglu H., Ferlini A., Wilson L., Dubowitz V., and Muntoni F. Prenatal diagnosis in merosin-deficient congenital muscular dystrophy. Neuromuscul. Disord. 7 (1997) 176-179
35. Vainzof M., Richard P., Herrmann R., Jimenez-Mallebrera C., Talim B., Yamamoto L.U., Ledeuil C., Mein R., Abbs S., Brockington M., Romero N.B., Zatz M., Topaloglu H., Voit T., Sewry C., Muntoni F., Guicheney P., and Tome F.M. Prenatal diagnosis in laminin alpha2 chain (merosin)-deficient congenital muscular dystrophy: a collective experience of five international centers. Neuromuscul. Disord. 9-10 (2005) 588-594
36. Voit T., Fardeau M., and Tome F.M. Prenatal detection of merosin expression in human placenta. Neuropediatrics 25 (1994) 332-333
37. Korhonen M., and Virtanen I. Immunohistochemical localization of laminin and fibronectin isoforms in human placental villi. J. Histochem. Cytochem. (2001) 313-322
38. Brockington M., Sewry C.A., Herrmann R., Naom I., Dearlove A., Rhodes M., Topaloglu H., Dubowitz V., Voit T., and Muntoni F. Assignment of a form of congenital muscular dystrophy with secondary merosin deficiency to chromosome 1q42. Am. J. Hum. Genet. 66 (2000) 428-435
39. Tezak Z., Prandini P., Boscaro M., Marin A., Devaney J., Marino M., Fanin M., Trevisan C.P., Park J., Tyson W., Finkel R., Garcia C., Angelini C., Hoffman E.P., and Pegoraro E. Clinical and molecular study in congenital muscular dystrophy with partial laminin alpha 2 (LAMA2) deficiency. Human Mutat. 21 (2003) 103-111
40. Nissinen M., Helbling-Leclerc A., Zhang X., Evangelista T., Topaloglu H., Cruaud C., Weissenbach J., Fardeau M., Tome F.M., Schwartz K., Tryggvason K., and Guicheney P. Substitution of a conserved cysteine-996 in a cysteine-rich motif of the laminin alpha2-chain in congenital muscular dystrophy with partial deficiency of the protein. Am. J. Hum. Genet. 58 (1996) 1177-1184
41. Allamand V., Sunada Y., Salih M.A., Straub V., Ozo C.O., Al-Turaiki M.H., Akbar M., Kolo T., Colognato H., Zhang X., Sorokin L.M., Yurchenco P.D., Tryggvason K., and Campbell K.P. Mild congenital muscular dystrophy in two patients with an internally deleted laminin alpha2-chain. Hum. Mol. Genet. 6 (1997) 747-752
42. Guo L.T., Zhang X.U., Kuang W., Xu H., Liu L.A., Vilquin J.T., Miyagoe-Suzuki Y., Takeda S., Ruegg M.A., Wewer U.M., and Engvall E. Laminin alpha2 deficiency and muscular dystrophy; genotype-phenotype correlation in mutant mice. Neuromuscul. Disord. 13 (2003) 207-215
43. Kuo H.J., Maslen C.L., Keene D.R., and Glanville R.W. Type VI collagen anchors endothelial basement membranes by interacting with type IV collagen. J. Biol. Chem. 272 (1997) 26522-26529
44. Miyagoe Y., Hanaoka K., Nonaka I., Hayasaka M., Nabeshima Y., Arahata K., Nabeshima Y., and Takeda S. Laminin alpha2 chain-null mutant mice by targeted disruption of the Lama2 gene: a new model of merosin (laminin 2)-deficient congenital muscular dystrophy. FEBS Lett. 415 (1997) 33-39
45. Sunada Y., Bernier S.M., Utani A., Yamada Y., and Campbell K.P. Identification of a novel mutant transcript of laminin alpha 2 chain gene responsible for muscular dystrophy and dysmyelination in dy2J mice. Hum. Mol. Genet. 4 (1995) 1055-1061
46. Xu H., Wu X.R., Wewer U.M., and Engvall E. Murine muscular dystrophy caused by a mutation in the laminin alpha 2 (Lama2) gene. Nat. Genet. 8 (1994) 297-302
47. Minetti C., Bado M., Morreale G., Pedemonte M., and Cordone G. Disruption of muscle basal lamina in congenital muscular dystrophy with merosin deficiency. Neurology 46 (1996) 1354-1358
48. Kuang W., Xu H., Vachon P.H., Liu L., Loechel F., Wewer U.M., and Engvall E. Merosin-deficient congenital muscular dystrophy. Partial genetic correction in two mouse models. J. Clin. Invest. 102 (1998) 844-852
49. Bentzinger C.F., Barzaghi P., Lin S., and Ruegg M.A. Overexpression of mini-agrin in skeletal muscle increases muscle integrity and regenerative capacity in laminin-alpha2-deficient mice. FASEB J. 19 (2005) 934-942
50. Moll J., Barzaghi P., Lin S., Bezakova G., Lochmuller H., Engvall E., Muller U., and Ruegg M.A. An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. Nature 413 (2001) 302-307
51. Qiao C., Li J., Zhu T., Draviam R., Watkins S., Ye X., Chen C., Li J., and Xiao X. Amelioration of laminin-alpha2-deficient congenital muscular dystrophy by somatic gene transfer of miniagrin. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 11999-12004
52. Gawlik K., Miyagoe-Suzuki Y., Ekblom P., Takeda S., and Durbeej M. Laminin alpha1 chain reduces muscular dystrophy in laminin alpha2 chain deficient mice. Hum. Mol. Genet. 13 (2004) 1775-1784
53. Hager M., Gawlik K., Nystrom A., Sasaki T., and Durbeej M. Laminin {alpha}1 chain corrects male infertility caused by absence of laminin {alpha}2 chain. Am. J. Pathol. 167 (2005) 822-833
54. Dominov J.A., Kravetz A.J., Ardelt M., Kostek C.A., Beermann M.L., and Miller J.B. Muscle-specific BCL2 expression ameliorates muscle disease in laminin {alpha}2-deficient, but not in dystrophin-deficient, mice. Hum. Mol. Genet. 14 (2005) 1029-1040
55. Girgenrath M., Dominov J.A., Kostek C.A., and Miller J.B. Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy. J. Clin. Invest. 114 (2004) 1635-1639
56. Nystrom A., Holmblad J., Pedrosa-Domellof F., Sasaki T., and Durbeej M. Extraocular muscle is spared upon complete laminin alpha2 chain deficiency: Comparative expression of laminin and integrin isoforms. Matrix Biol. (2006) (2006) [Epub ahead of print]
57. Cohn R.D. Dystroglycan: important player in skeletal muscle and beyond. Neuromuscul. Disord. 15 (2005) 207-217
58. Martin P.T. The dystroglycanopathies: the new disorders of O-linked glycosylation. Semin. Pediatr. Neurol. 12 (2005) 152-158
59. Muntoni F. Journey into muscular dystrophies caused by abnormal glycosylation. Acta Myol. 23 (2004) 79-84
60. Henry M.D., and Campbell K.P. A role for dystroglycan in basement membrane assembly. Cell 95 (1998) 859-870
61. Williamson R.A., Henry M.D., Daniels K.J., Hrstka R.F., Lee J.C., Sunada Y., Ibraghimov-Beskrovnaya O., and Campbell K.P. Dystroglycan is essential for early embryonic development: disruption of Reichert's membrane in Dag1-null mice]. Hum. Mol. Genet. 6 (1997) 831-841
62. Cohn R.D., Henry M.D., Michele D.E., Barresi R., Saito F., Moore S.A., Flanagan J.D., Skwarchuk M.W., Robbins M.E., Mendell J.R., Williamson R.A., and Campbell K.P. Disruption of DAG1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration. Cell 110 (2002) 639-648
63. Cote P.D., Moukhles H., Lindenbaum M., and Carbonetto S. Chimaeric mice deficient in dystroglycans develop muscular dystrophy and have disrupted myoneural synapses. Nat. Genet. 23 (1999) 338-342
64. Barresi R., and Campbell K.P. Dystroglycan: from biosynthesis to pathogenesis of human disease. J. Cell. Sci. 119 (2006) 199-207
65. Ervasti J.M., Ohlendieck K., Kahl S.D., Gaver M.G., and Campbell K.P. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 345 (1990) 315-319
66. Ervasti J.M., and Campbell K.P. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J. Cell Biol. (1993) 809-823
67. Sugita S., Saito F., Tang J., Satz J., Campbell K.P., and Sudhof T.C. A stoichiometric complex of neurexins and dystroglycan in brain. J. Cell Biol. 154 (2001) 435-445
68. Campanelli J.T., Roberds S.L., Campbell K.P., and Scheller R.H. A role for dystrophin-associated glycoproteins and utrophin in agrin-induced AChR clustering. Cell 77 (1994) 633-674
69. Gee S.H., Montanaro F., Lindenbaum M.H., and Carbonetto S. Dystroglycan-alpha, a dystrophin-associated glycoprotein, is a functional agrin receptor. Cell 77 (1994) 675-686
70. Ibraghimov-Beskrovnaya O., Ervasti J.M., Leveille C.J., Slaughter C.A., Sernett S.W., and Campbell K.P. Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 355 (1992) 696-702
71. Michele D.E., Barresi R., Kanagawa M., Saito F., Cohn R.D., Satz J.S., Dollar J., Nishino I., Kelley R.I., Somer H., Straub V., Mathews K.D., Moore S.A., and Campbell K.P. Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 418 (2002) 417-422
72. Grewal P.K., Holzfeind P.J., Bittner R.E., and Hewitt J.E. Mutant glycosyltransferase and altered glycosylation of alpha-dystroglycan in the myodystrophy mouse. Nat. Genet. 28 (2001) 151-154
73. Holzfeind P.J., Grewal P.K., Reitsamer H.A., Kechvar J., Lassmann H., Hoeger H., Hewitt J.E., and Bittner R.E. Skeletal, cardiac and tongue muscle pathology, defective retinal transmission, and neuronal migration defects in the Large(myd) mouse defines a natural model for glycosylation-deficient muscle-eye-brain disorders. Hum. Mol. Genet. 11 (2002) 2673-2687
74. Longman C., Brockington M., Torelli S., Jimenez-Mallebrera C., Kennedy C., Khalil N., Feng L., Saran R.K., Voit T., Merlini L., Sewry C.A., Brown S.C., and Muntoni F. Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan. Hum. Mol. Genet. 12 (2003) 2853-2861
75. Kanagawa M., Saito F., Kunz S., Yoshida-Moriguchi T., Barresi R., Kobayashi Y.M., Muschler J., Dumanski J.P., Michele D.E., Oldstone M.B., and Campbell K.P. Molecular recognition by LARGE is essential for expression of functional dystroglycan. Cell 117 (2004) 953-964
76. Barresi R., Michele D.E., Kanagawa M., Harper H.A., Dovico S.A., Satz J.S., Moore S.A., Zhang W., Schachter H., Dumanski J.P., Cohn R.D., Nishino I., and Campbell K.P. LARGE can functionally bypass alpha-dystroglycan glycosylation defects in distinct congenital muscular dystrophies. Nat. Med. 10 (2004) 696-703
77. Cormand B., Avela K., Pihko H., Santavuori P., Talim B., Topaloglu H., de la Chapelle A., and Lehesjoki A.E. Assignment of the muscle-eye-brain disease gene to 1p32-p34 by linkage analysis and homozygosity mapping. Am. J. Hum. Genet. 64 (1999) 126-135
78. Dobyns W.B., Pagon R.A., Armstrong D., Curry C.J., Greenberg F., Grix A., Holmes L.B., Laxova R., Michels V.V., Robinow M., et al. Diagnostic criteria for Walker-Warburg syndrome. Am. J. Med. Genet. 32 (1989) 195-210
79. Moore S.A., Saito F., Chen J., Michele D.E., Henry M.D., Messing A., Cohn R.D., Ross-Barta S.E., Westra S., Williamson R.A., Hoshi T., and Campbell K.P. Deletion of brain dystroglycan recapitulates aspects of congenital muscular dystrophy. Nature 418 (2002) 422-425
80. Beltran-Valero de Bernabe D., Currier S., Steinbrecher A., Celli J., van Beusekom E., van der Zwaag B., Kayserili H., Merlini L., Chitayat D., Dobyns W.B., Cormand B., Lehesjoki A.E., Cruces J., Voit T., Walsh C.A., van Bokhoven H., and Brunner H.G. Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome. Am. J. Hum. Genet. 71 (2002) 1033-1043
81. van Reeuwijk J., Maugenre S., van den Elzen C., Verrips A., Bertini E., Muntoni F., Merlini L., Scheffer H., Brunner H.G., Guicheney P., and van Bokhoven H. The expanding phenotype of POMT1 mutations: from Walker-Warburg syndrome to congenital muscular dystrophy, microcephaly, and mental retardation. Human Mutat. 27 (2006) 453-459
82. D'Amico A., Tessa A., Bruno C., Petrini S., Biancheri R., Pane M., Pedemonte M., Ricci E., Falace A., Rossi A., Mercuri E., Santorelli F.M., and Bertini E. Expanding the clinical spectrum of POMT1 phenotype. Neurology 66 (2006) 1564-1567
83. van Reeuwijk J., Janssen M., van den Elzen C., Beltran-Valero de Bernabe D., Sabatelli P., Merlini L., Boon M., Scheffer H., Brockington M., Muntoni F., Huynen M.A., Verrips A., Walsh C.A., Barth P.G., Brunner H.G., and van Bokhoven H. POMT2 mutations cause alpha-dystroglycan hypoglycosylation and Walker-Warburg syndrome. J. Med. Genet. 42 (2005) 907-912
84. Jimenez-Mallebrera C., Torelli S., Brown S.C., Feng L., Brockington M., Sewry C.A., Beltran-Valero De Bernabe D., and Muntoni F. Profound skeletal muscle depletion of alpha-dystroglycan in Walker-Warburg syndrome. Eur. J. Paediatr. Neurol. 7 (2003) 129-137
85. Kim D.S., Hayashi Y.K., Matsumoto H., Ogawa M., Noguchi S., Murakami N., Sakuta R., Mochizuki M., Michele D.E., Campbell K.P., Nonaka I., and Nishino I. POMT1 mutation results in defective glycosylation and loss of laminin-binding activity in alpha-DG. Neurology 62 (2004) 1011
86. Sabatelli P., Columbaro M., Mura I., Capanni C., Lattanzi G., Maraldi N.M., Beltran-Valero de Barnabe D., van Bokoven H., Squarzoni S., and Merlini L. Extracellular matrix and nuclear abnormalities in skeletal muscle of a patient with Walker-Warburg syndrome caused by POMT1 mutation. Biochim. Biophys. Acta 1638 (2003) 57-62
87. Cormand B., Pihko H., Bayes M., Valanne L., Santavuori P., Talim B., Gershoni-Baruch R., Ahmad A., van Bokhoven H., Brunner H.G., Voit T., Topaloglu H., Dobyns W.B., and Lehesjoki A.E. Clinical and genetic distinction between Walker-Warburg syndrome and muscle-eye-brain disease. Neurology 56 (2001) 1059-1069
88. Diesen C., Saarinen A., Pihko H., Rosenlew C., Cormand B., Dobyns W.B., Dieguez J., Valanne L., Joensuu T., and Lehesjoki A.E. POMGnT1 mutation and phenotypic spectrum in muscle-eye-brain disease. J. Med. Genet. 41 (2004) e115
89. Yoshida A., Kobayashi K., Manya H., Taniguchi K., Kano H., Mizuno M., Inazu T., Mitsuhashi H., Takahashi S., Takeuchi M., Herrmann R., Straub V., Talim B., Voit T., Topaloglu H., Toda T., and Endo T. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev. Cell 1 (2001) 717-724
90. Taniguchi K., Kobayashi K., Saito K., Yamanouchi H., Ohnuma A., Hayashi Y.K., Manya H., Jin D.K., Lee M., Parano E., Falsaperla R., Pavone P., Van Coster R., Talim B., Steinbrecher A., Straub V., Nishino I., Topaloglu H., Voit T., Endo T., and Toda T. Worldwide distribution and broader clinical spectrum of muscle-eye-brain disease. Hum. Mol. Genet. 12 (2003) 527-534
91. Zhang W., Vajsar J., Cao P., Breningstall G., Diesen C., Dobyns W., Herrmann R., Lehesjoki A.E., Steinbrecher A., Talim B., Toda T., Topaloglu H., Voit T., and Schachter H. Enzymatic diagnostic test for muscle-eye-brain type congenital muscular dystrophy using commercially available reagents. Clin. Biochem. 36 (2003) 339-344
92. Vajsar J., Zhang W., Dobyns W.B., Biggar D., Holden K.R., Hawkins C., Ray P., Olney A.H., Burson C.M., Srivastava A.K., and Schachter H. Carriers and patients with muscle-eye-brain disease can be rapidly diagnosed by enzymatic analysis of fibroblasts and lymphoblasts. Neuromuscul. Disord. 16 (2006) 132-136
93. Liu J., Ball S.L., Yang Y., Mei P., Zhang L., Shi H., Kaminski H.J., Lemmon V.P., and Hu H. A genetic model for muscle-eye-brain disease in mice lacking protein O-mannose 1,2-N-acetylglucosaminyltransferase (POMGnT1). Mech. Dev. 123 (2006) 228-240
94. Toda T., Kobayashi K., Kondo-Iida E., Sasaki J., and Nakamura Y. The Fukuyama congenital muscular dystrophy story. Neuromuscul. Disord. 10 (2000) 153-159
95. Nakanishi T., Sakauchi M., Kaneda Y., Tomimatsu H., Saito K., Nakazawa M., and Osawa M. Cardiac involvement in Fukuyama-type congenital muscular dystrophy. Pediatrics 117 (2006) 1187-1192
96. Kobayashi K., Nakahori Y., Miyake M., Matsumura K., Kondo-Iida E., Nomura Y., Segawa M., Yoshioka M., Saito K., Osawa M., Hamano K., Sakakihara Y., Nonaka I., Nakagome Y., Kanazawa I., Nakamura Y., Tokunaga K., and Toda T. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 394 (1998) 388-392
97. Kondo-Iida E., Kobayashi K., Watanabe M., Sasaki J., Kumagai T., Koide H., Saito K., Osawa M., Nakamura Y., and Toda T. Novel mutations and genotype-phenotype relationships in 107 families with Fukuyama-type congenital muscular dystrophy (FCMD). Hum. Mol. Genet. 8 (1999) 2303-2309
98. Silan F., Yoshioka M., Kobayashi K., Simsek E., Tunc M., Alper M., Cam M., Guven A., Fukuda Y., Kinoshita M., Kocabay K., and Toda T. A new mutation of the fukutin gene in a non-Japanese patient. Ann. Neurol. 53 (2003) 392-396
99. Breton C., Mucha J., and Jeanneau C. Structural and functional features of glycosyltransferases. Biochimie 83 (2001) 713-718
100. Hayashi Y.K., Ogawa M., Tagawa K., Noguchi S., Ishihara T., Nonaka I., and Arahata K. Selective deficiency of alpha-dystroglycan in Fukuyama-type congenital muscular dystrophy. Neurology 57 (2001) 115-121
101. Takeda S., Kondo M., Sasaki J., Kurahashi H., Kano H., Arai K., Misaki K., Fukui T., Kobayashi K., Tachikawa M., Imamura M., Nakamura Y., Shimizu T., Murakami T., Sunada Y., Fujikado T., Matsumura K., Terashima T., and Toda. T. Fukutin is required for maintenance of muscle integrity, cortical histiogenesis and normal eye development. Hum. Mol. Genet. 12 (2003) 1449-1459
102. Brockington M., Blake D.J., Prandini P., Brown S.C., Torelli S., Benson M.A., Ponting C.P., Estournet B., Romero N.B., Mercuri E., Voit T., Sewry C.A., Guicheney P., and Muntoni F. Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. Am. J. Hum. Genet. 69 (2001) 1198-1209
103. Beltran-Valero de Bernabe D., Voit T., Longman C., Steinbrecher A., Straub V., Yuva Y., Herrmann R., Sperner J., Korenke C., Diesen C., Dobyns W.B., Brunner H.G., van Bokhoven H., Brockington M., and Muntoni F. Mutations in the FKRP gene can cause muscle-eye-brain disease and Walker-Warburg syndrome. J. Med. Genet. 41 (2004) e61
104. Topaloglu H., Brockington M., Yuva Y., Talim B., Haliloglu G., Blake D., Torelli S., Brown S.C., and Muntoni F. FKRP gene mutations cause congenital muscular dystrophy, mental retardation, and cerebellar cysts. Neurology 60 (2003) 988-992
105. Brown S.C., Torelli S., Brockington M., Yuva Y., Jimenez C., Feng L., Anderson L., Ugo I., Kroger S., Bushby K., Voit T., Sewry C., and Muntoni F. Abnormalities in alpha-dystroglycan expression in MDC1C and LGMD2I muscular dystrophies. Am. J. Pathol. 164 (2004) 727-737
106. Mercuri E., Brockington M., Straub V., Quijano-Roy S., Yuva Y., Herrmann R., Brown S.C., Torelli S., Dubowitz V., Blake D.J., Romero N.B., Estournet B., Sewry C.A., Guicheney P., Voit T., and Muntoni F. Phenotypic spectrum associated with mutations in the fukutin-related protein gene. Ann. Neurol. 53 (2003) 537-542
107. de Paula F., Vieira N., Starling A., Yamamoto L.U., Lima B., de Cassia Pavanello R., Vainzof M., Nigro V., and Zatz M. Asymptomatic carriers for homozygous novel mutations in the FKRP gene: the other end of the spectrum. Eur. J. Hum. Genet. 11 (2003) 923-930
108. Harel T., Goldberg Y., Shalev S.A., Chervinski I., Ofir R., and Birk O.S. Limb-girdle muscular dystrophy 2I: phenotypic variability within a large consanguineous Bedouin family associated with a novel FKRP mutation. Eur. J. Hum. Genet. 12 (2004) 38-43
109. Esapa C.T., Benson M.A., Schroder J.E., Martin-Rendon E., Brockington M., Brown S.C., Muntoni F., Kroger S., and Blake D.J. Functional requirements for fukutin-related protein in the Golgi apparatus. Hum. Mol. Genet. 11 (2002) 3319-3331
110. Esapa C.T., McIlhinney R.A., and Blake D.J. Fukutin-related protein mutations that cause congenital muscular dystrophy result in ER-retention of the mutant protein in cultured cells. Hum. Mol. Genet. 14 (2005) 295-305
111. Ullrich O. Kongenitale atonisch-sklerotische Muskeldystrophie, ein weiterer Typus der heredodegeneration Erkrankungen des neuromuskularen Systems. Z. Ges. Neurol. Psychiat. 126 (1930) 171-201
112. Demir E., Sabatelli P., Allamand V., Ferreiro A., Moghadaszadeh B., Makrelouf M., Topaloglu H., Echenne B., Merlini L., and Guicheney P. Mutations in COL6A3 cause severe and mild phenotypes of Ullrich congenital muscular dystrophy. Am. J. Hum. Genet. 70 (2002) 1446-1458
113. Giusti B., Lucarini L., Pietroni V., Lucioli S., Bandinelli B., Sabatelli P., Squarzoni S., Petrini S., Gartioux C., Talim B., Roelens F., Merlini L., Topaloglu H., Bertini E., Guicheney P., and Pepe G. Dominant and recessive COL6A1 mutations in Ullrich scleroatonic muscular dystrophy. Ann. Neurol. 58 (2005) 400-410
114. Pan T.C., Zhang R.Z., Sudano D.G., Marie S.K., Bonnemann C.G., and Chu M.L. New molecular mechanism for Ullrich congenital muscular dystrophy: a heterozygous in-frame deletion in the COL6A1 gene causes a severe phenotype. Am. J. Hum. Genet. 73 (2003) 355-369
115. Vanegas O.C., Zhang R.Z., Sabatelli P., Lattanzi G., Bencivenga P., Giusti B., Columbaro M., Chu M.L., Merlini L., and Pepe G. Novel COL6A1 splicing mutation in a family affected by mild Bethlem myopathy. Muscle Nerve 25 (2002) 513-519
116. Hessle H., and Engvall E. Type VI collagen. Studies on its localization, structure, and biosynthetic form with monoclonal antibodies. J. Biol. Chem. 259 (1984) 3955-3961
117. von der Mark K., van Menxel M., and Weidemann H. Isolation and characterization of a precursor form of M collagen from embryonic chicken cartilage. Eur. J. Biochem. 138 (1984) 629-633
118. Ishikawa H., Sugie K., Murayama K., Ito M., Minami N., Nishino I., and Nonaka I. Ullrich disease: collagen VI deficiency: EM suggests a new basis for muscular weakness. Neurology 59 (2002) 920-923
119. Atkinson J.C., Ruhl M., Becker J., Ackermann R., and Schuppan D. Collagen VI regulates normal and transformed mesenchymal cell proliferation in vitro. Exp. Cell Res. 228 (1996) 283-291
120. Ruhl M., Johannsen M., Atkinson J., Manski D., Sahin E., Somasundaram R., Riecken E.O., and Schuppan D. Soluble collagen VI induces tyrosine phosphorylation of paxillin and focal adhesion kinase and activates the MAP kinase erk2 in fibroblasts. Exp. Cell Res. 250 (1999) 548-557
121. Ruhl M., Sahin E., Johannsen M., Somasundaram R., Manski D., Riecken E.O., and Schuppan D. Soluble collagen VI drives serum-starved fibroblasts through S phase and prevents apoptosis via down-regulation of Bax. J. Biol. Chem. 274 (1999) 34361-34368
122. Mercuri E., Yuva Y., Brown S.C., Brockington M., Kinali M., Jungbluth H., Feng L., Sewry C.A., and Muntoni F. Collagen VI involvement in Ullrich syndrome: a clinical, genetic, and immunohistochemical study. Neurology 58 (2002) 1354-1359
123. Demir E., Ferreiro A., Sabatelli P., Allamand V., Makri S., Echenne B., Maraldi M., Merlini L., Topaloglu H., and Guicheney P. Collagen VI status and clinical severity in Ullrich congenital muscular dystrophy: phenotype analysis of 11 families linked to the COL6 loci. Neuropediatrics 35 (2004) 103-112
124. Squarzoni S., Sabatelli P., Bergamin N., Guicheney P., Demir E., Merlini L., Lattanzi G., Ognibene A., Capanni C., Mattioli E., Columbaro M., Bonaldo P., and Maraldi N.M. Ultrastructural defects of collagen VI filaments in an Ullrich syndrome patient with loss of the alpha3(VI) N10-N7 domains. J. Cell. Physiol. 206 (2006) 160-166
125. Mercuri E., Lampe A., Allsop J., Knight R., Pane M., Kinali M., Bonnemann C., Flanigan K., Lapini I., Bushby K., Pepe G., and Muntoni F. Muscle MRI in Ullrich congenital muscular dystrophy and Bethlem myopathy. Neuromuscul. Disord. 15 (2005) 303-310
126. Brockington M., Brown S.C., Lampe A., Yuva Y., Feng L., Jimenez-Mallebrera C., Sewry C.A., Flanigan K.M., Bushby K., and Muntoni F. Prenatal diagnosis of Ullrich congenital muscular dystrophy using haplotype analysis and collagen VI immunocytochemistry. Prenat. Diagn. 24 (2004) 440-444
127. Reed U.C., Ferreira L.G., Liu E.C., Resende M.B., Carvalho M.S., Marie S.K., and Scaff M. Ullrich congenital muscular dystrophy and Bethlem myopathy: clinical and genetic heterogeneity. Arq. Neuro-Psiquiatr. 63 (2005) 785-790
128. Lampe A.K., Dunn D.M., von Niederhausern A.C., Hamil C., Aoyagi A., Laval S.H., Marie S.K., Chu M.L., Swoboda K., Muntoni F., Bonnemann C.G., Flanigan K.M., Bushby K.M., and Weiss R.B. Automated genomic sequence analysis of the three collagen VI genes: applications to Ullrich congenital muscular dystrophy and Bethlem myopathy. J. Med. Genet. 42 (2005) 108-120
129. Kirschner J., Hausser I., Zou Y., Schreiber G., Christen H.J., Brown S.C., Anton-Lamprecht I., Muntoni F., Hanefeld F., and Bonnemann C.G. Ullrich congenital muscular dystrophy: connective tissue abnormalities in the skin support overlap with Ehlers-Danlos syndromes. Am. J. Med. Genet., Part A 132 (2005) 296-301
130. Bonaldo P., Braghetta P., Zanetti M., Piccolo S., Volpin D., and Bressan G.M. Collagen VI deficiency induces early onset myopathy in the mouse: an animal model for Bethlem myopathy. Hum. Mol. Genet. 7 (1998) 2135-2140
131. Irwin W.A., Bergamin N., Sabatelli P., Reggiani C., Megighian A., Merlini L., Braghetta P., Columbaro M., Volpin D., Bressan G.M., Bernardi P., and Bonaldo P. Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency. Nat. Genet. 35 2003 (2003) 367-371
132. Usuki F., Yamashita A., Kashima I., Higuchi I., Osame M., and Ohno S. Specific inhibition of nonsense-mediated mRNA decay components, SMG-1 or Upf1, rescues the phenotype of ullrich disease fibroblasts. Mol. Ther. 14 (2006) 351-360
133. Allamand V., Richard P., Lescure A., Ledeuil C., Desjardin D., Petit N., Gartioux C., Ferreiro A., Krol A., Pellegrini N., Urtizberea J.A., and Guicheney P. A single homozygous point mutation in a 3′untranslated region motif of selenoprotein N mRNA causes SEPN1-related myopathy. EMBO Rep. 7 (2006) 450-454
134. Moghadaszadeh B., Petit N., Jaillard C., Brockington M., Roy S.Q., Merlini L., Romero N., Estournet B., Desguerre I., Chaigne D., Muntoni F., Topaloglu H., and Guicheney P. Mutations in SEPN1 cause congenital muscular dystrophy with spinal rigidity and restrictive respiratory syndrome. Nat. Genet. 29 2001 (2003) 17-18
135. Petit N., Lescure A., Rederstorff M., Krol A., Moghadaszadeh B., Wewer U.M., and Guicheney P. Selenoprotein N: an endoplasmic reticulum glycoprotein with an early developmental expression pattern. Hum. Mol. Genet. 12 (2003) 1045-1053
136. Ferreiro A., Quijano-Roy S., Pichereau C., Moghadaszadeh B., Goemans N., Bonnemann C., Jungbluth H., Straub V., Villanova M., Leroy J.P., Romero N.B., Martin J.J., Muntoni F., Voit T., Estournet B., Richard P., Fardeau M., and Guicheney P. Mutations of the selenoprotein N gene, which is implicated in rigid spine muscular dystrophy, cause the classical phenotype of multiminicore disease: reassessing the nosology of early-onset myopathies. Am. J. Hum. Genet. 71 (2002) 739-749
137. Ferreiro A., Ceuterick-de Groote C., Marks J.J., Goemans N., Schreiber G., Hanefeld F., Fardeau M., Martin J.J., Goebel H.H., Richard P., Guicheney P., and Bonnemann C.G. Desmin-related myopathy with Mallory body-like inclusions is caused by mutations of the selenoprotein N gene. Ann. Neurol. 55 (2004) 676-686
138. Mercuri E., Talim B., Moghadaszadeh B., Petit N., Brockington M., Counsell S., Guicheney P., Muntoni F., and Merlini L. Clinical and imaging findings in six cases of congenital muscular dystrophy with rigid spine syndrome linked to chromosome 1p (RSMD1). Neuromuscul. Disord. 12 (2002) 631-638
139. Okamoto Y., Takashima H., Higuchi I., Matsuyama W., Suehara M., Nishihira Y., Hashiguchi A., Hirano R., Ng A.R., Nakagawa M., Izumo S., Osame M., and Arimura K. Molecular mechanism of rigid spine with muscular dystrophy type 1 caused by novel mutations of selenoprotein N gene. Neurogenetics (2006) [Epub ahead of print]
140. Burkin D.J., and Kaufman S.J. The alpha7beta1 integrin in muscle development and disease. Cell Tissue Res. 296 (1999) 183-190
141. Velling T., Collo G., Sorokin L., Durbeej M., Zhang H., and Gullberg D. Distinct alpha 7A beta 1 and alpha 7B beta 1 integrin expression patterns during mouse development: alpha 7A is restricted to skeletal muscle but alpha 7B is expressed in striated muscle, vasculature, and nervous system. Dev. Dyn. 207 (1996) 355-371
142. Martin P.T., Kaufman S.J., Kramer R.H., and Sanes J.R. Synaptic integrins in developing, adult, and mutant muscle: selective association of alpha1, alpha7A, and alpha7B integrins with the neuromuscular junction. Dev. Biol. 174 (1996) 125-139
143. Mayer U., Saher G., Fassler R., Bornemann A., Echtermeyer F., von der Mark H., Miosge N., Poschl E., and von der Mark K. Absence of integrin alpha 7 causes a novel form of muscular dystrophy. Nat. Genet. 17 (1997) 318-323
144. Flintoff-Dye N.L., Welser J., Rooney J., Scowen P., Tamowski S., Hatton W., and Burkin D.J. Role for the alpha7beta1 integrin in vascular development and integrity. Dev. Dyn. 234 (2005) 11-21
145. Wang W., Wu W., Desai T., Ward D.C., and Kauffman S.J. Localization of the alpha 7 integrin gene (ITGA7) on human chromosome 12q13: clustering of integrin and Hox genes implies parallel evolution of these gene families. Genomics 26 (1995) 568-570
146. Hayashi Y.K., Chou F.L., Engvall E., Ogawa M., Matsuda C., Hirabayashi S., Yokochi K., Ziober B.L., Kramer R.H., Kaufman S.J., Ozawa E., Goto Y., Nonaka I., Tsukahara T., Wang J.Z., Hoffman E.P., and Arahata K. Mutations in the integrin alpha7 gene cause congenital myopathy. Nat. Genet. 19 (1998) 94-97
147. Burkin D.J., Wallace G.Q., Milner D.J., Chaney E.J., Mulligan J., and Kauffman S.J. Transgenic expression of {alpha}7{beta}1 integrin maintains muscle integrity, increases regenerative capacity, promotes hypertrophy, and reduces cardiomyopathy in dystrophic mice. Am. J. Pathol. 166 (2005) 253-263
148. Burkin D.J., Wallace G.Q., Nicol K.J., Kaufman D.J., and Kauffman S.J. Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice. J. Cell Biol. 152 (2001) 11218-12007
149. Rooney J.E., Welser J.V., Dechert M.A., Flintoff-Dye N.L., Kaufman S.J., and Burkin D.J. Severe muscular dystrophy in mice that lack dystrophin and {alpha}7 integrin. J. Cell. Sci. 119 (2006) 2185-2195